michigan glp-1 diarrhea lawyer Ozempic Lawsuit Ozempic Lawsuit – July 2026
Description
Semaglutide and tirzepatide are relatively newer weight loss medications, meaning many plasma centers are still developing clear protocols for their donors
They provide the insulin hormone directly rather than stimulating its production
The first DPP-4 inhibitor, sitagliptin, was approved by the FDA in 2006 and by the EMA in 2007
Individuals experiencing gastroparesis or other health issues following the use of Ozempic or other GLP-1 agonists may qualify to participate in the lawsuit
